FGI-104
Legal status
Legal status
Identifiers
  • 4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol
PubChem CID
ChemSpider
Chemical and physical data
FormulaC28H30ClN3O3
Molar mass492.02 g·mol−1
3D model (JSmol)
  • c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO
  • InChI=1S/C28H30ClN3O3/c1-4-32(5-2)16-20-12-22(31-25-10-11-30-26-14-21(29)8-9-23(25)26)15-24(28(20)34)18-6-7-19(17-33)27(13-18)35-3/h6-15,33-34H,4-5,16-17H2,1-3H3,(H,30,31)
  • Key:OFXBJOIYAJBMNY-UHFFFAOYSA-N

FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including hepatitis B, hepatitis C, HIV, Ebola virus, and Venezuelan equine encephalitis virus. [1]

Mechanism

The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.[2][3]

See also

References

  1. ^ Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009). "FGI-104: a broad-spectrum small molecule inhibitor of viral infection". American Journal of Translational Research. 1 (1): 87–98. doi:10.1016/j.antiviral.2009.02.082. PMC 2776286. PMID 19966942.
  2. ^ Janeba Z (November 2015). "Development of Small-Molecule Antivirals for Ebola". Medicinal Research Reviews. 35 (6): 1175–94. doi:10.1002/med.21355. PMC 7168439. PMID 26172225.
  3. ^ Saxena A, Ferri M (2015). "Clinical Management of Ebola Virus Disease: Current and Future Approaches". In Saxena A (ed.). Communicable Diseases of the Developing World. Topics in Medicinal Chemistry. Vol. 29. Cham: Springer. pp. 1–36. doi:10.1007/7355_2015_5003. ISBN 978-3-319-78252-2.
Categories